Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with b and non-b subtype hiv-1 viruses

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1237-1242

  Lambert Niclot, S ^a   Charpentier, C ^b   Storto, A ^b   Fofana, D B ^a   Soulie C ^a   Fourati, S ^a   Visseaux, B ^b   Wirden, M ^a   Morand Joubert, L ^a   Masquelier, B ^c   Flandre, P ^a   Calvez, V ^a   Descamps, D ^b   Marcelin, A G ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

NNRTIs; Non nucleoside reverse transcriptase inhibitors; Primary resistance

Indexed keywords

EFAVIRENZ; EMTRICITABINE; NEVIRAPINE; RILPIVIRINE; TENOFOVIR;

ALGORITHM; ARTICLE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1B; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE;

NNRTIS; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS; PRIMARY RESISTANCE;

ADENINE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; NITRILES; ORGANOPHOSPHONATES; PREVALENCE; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84884395662     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt003     Document Type: Article

References (29)

1. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
2. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: 65-71.
3. Yeni P. Rapport 2010 sur la prise en charge médicale des personnes infectées par le VIH sous la direction du Pr. Patrick Yéni-Ministère en charge de la santé . http://www.sante.gouv.fr/rapport-2010-sur-la-priseen- charge-medicale-des-personnes-infectees-par-le-vih-sous-la-directiondu- pr-patrick-yeni.html (28 December 2012, date last accessed).
4. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http:// www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf? bcsi_scan_CBA24F92DB3F63E2=0&bcsi_scan_ filename=adultandadolescentgl. pdf (28 December 2012, date last accessed).
5. Ghosn J, Chaix M-L, Delaugerre C. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev 2009; 11: 165-73.
6. Boehringer-Ingelheim. FDA Label for Viramune (Nevaripine) Tablets and Oral Suspension. 2008. http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+ Information/PIs/Viramune/Viramune.pdf (28 December 2012, date last accessed).
7. Bristol-Meyers Squibb Company. FDA Label for Sustiva (Efavirenz) Capsules and Tablets. 2009. http://packageinserts.bms.com/pi/pi_sustiva. pdf (28 December 2012, date last accessed).
8. Pé rez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002; 3: 279-86.
9. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63.
10. Deeks ED, Keating GM. Etravirine. Drugs 2008; 68: 2357-72.
11. European Medicines Agency. Edurantw 25 mg Film-Coated Tablets: Summary of Product Characteristics. 2012. http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/ WC500118874.pdf (28 December 2012, date last accessed).
12. Tibotec Pharmaceuticals. EdurantTM (Rilpivirine) Tablets: US Prescribing Information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2011/202022s000lbl.pdf (28 December 2012, date last accessed).
13. Gilead Sciences Inc. FDA Label for COMPLERATM (Emtricitabine/ Rilpivirine/Tenofovir Disoproxil Fumarate) Tablets (package insert). 2012. http://www.gilead.com/pdf/complera_pi.pdf (28 December 2012, date last accessed).
14. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54: 718-27.
15. Guillemont J, Pasquier E, Palandjian P, et al. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem 2005; 48: 2072-9.
16. Janssen PAJ, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005; 48: 1901-9.
17. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24: 55-65.
18. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 2012; 28: 437-46.
19. Cohen CJ, Molina J-M, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012; 60: 33-42.
20. Molina J-M, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-46.
21. Johnson VA, Calvez V, Günthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156-64.
22. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012; 59: 39-46.
23. Vingerhoets J, Rimsky L, Van Eygen V, et al. Preexisting mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virologic response. Antivir Ther 2012; doi:10.3851/IMP2358.
24. Van Eygen V, Thys K, Vingerhoets J, et al. Deep sequencing analysis of baseline samples from patients treated with rilpivirine in the Phase III studies ECHO and THRIVE shows no association between the presence of minority resistance-associated variants and virological failure. In: Abstracts of the International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Sitges, Spain, 2012. Abstract 27. Antivir Ther 2012; 17 Suppl 1: A35.
25. Haddad M, Napolitano LA, Paquet AC, et al. Impact of HIV-1 reverse transcriptase E138 mutations on rilpivirine drug susceptibility. In: Abstracts of the International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, Mexico. Abstract 10. Antivir Ther 2011; 16 Suppl 1: A18.
26. Marcelin AG, Descamps D, Tamalet C, et al. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen. Antivir Ther 2012; 17: 119-23.
27. Tambuyzer L, Nijs S, Daems B, et al. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr 2011; 58: 18-22.
28. Reinheimer C, Doerr HW, Stürmer M. Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database. J Clin Virol 2012; 53: 248-50.
29. Descamps D, Assoumou L, Charpentier C, et al. Stable prevalence of transmitted drug resistance mutations in antiretroviral-naive chronically HIV-infected patients between 2006/07 and 2010/11 in France. In: Abstracts of the Nineteenth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2012. Poster 733. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.